Danyi Wen, Shanghai LIDE Biotech, Stefan Jellbauer, Mitra Biotech, Lakshmi Santhosh Maithel, Repositi
The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in 2 people in the UK and 1 in 2 men/1 in 3 women in the US will experience it at some stage in their lives. And yet the picture for patients is an improving one.
The move towards immunotherapies heralds much promise and this is potentially just the beginning. As cancer is understood increasingly not by type, or even tumour type but specific mutation the era of personalised oncological therapies is visible.
To delve further into this pharmaphorum is pleased to present an exclusive online discussion.
Bringing together experts at the cutting edge of this field it aims to interrogate where we are in terms of this shift towards personalised oncology, what this means in terms of the development pathway and looks at the approaches which could (and will) fully evolve the way that cancer treatments are developed in terms of efficacy, approach and outcome.
this free to attend event will cover a number of topics critical to the future of oncology including:
•The changing face of cancer: how do we define it now?
•Personalised medicine in practice – where are we now in cancer?
•What are the implications from these changes for clinical trials?
•How the shift towards cancer as a phenotype/genotype is being applied in clinical trials and how they are run
•What are co-clinical trials and why could they hold the key to answering unmet need in cancer treatment and beyond into broader drug development?
•Modelling for the future of cancer – can this be done for personalised therapies?